Indaptus Therapeutics (NASDAQ:INDP) Stock Falls 5.7% – Here’s Why

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s stock price fell 5.7% during mid-day trading on Friday. The stock traded as low as $3.75 and last traded at $3.77. 137,725 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 629,845 shares. The stock had previously closed at $4.00.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Friday, July 17th. Wall Street Zen raised Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Indaptus Therapeutics has a consensus rating of “Sell”.

Indaptus Therapeutics Stock Performance

The stock has a 50-day moving average of $1.91 and a two-hundred day moving average of $2.24. The company has a market cap of $475.00 million, a P/E ratio of -0.56 and a beta of 1.17.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Thursday, August 13th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.55.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.